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Abstract
KRAS is one of the most commonly mutated oncogene and a negative predictive factor for a number of targeted therapies.
Therefore, the development of targeting strategies against mutant KRAS is urgently needed. One potential strategy involves
disruption of K-Ras membrane localization, which is necessary for its proper function. In this review, we summarize the current
data about the importance of membrane-anchorage of K-Ras and provide a critical evaluation of this targeting paradigm focusing
mainly on prenylation inhibition. Additionally, we performed a RAS mutation-specific analysis of prenylation-related drug
sensitivity data from a publicly available database (https://depmap.org/repurposing/) of three classes of prenylation inhibitors:
statins, N-bisphosphonates, and farnesyl-transferase inhibitors. We observed significant differences in sensitivity to N-
bisphosphonates and farnesyl-transferase inhibitors depending on KRAS mutational status and tissue of origin. These observa-
tions emphasize the importance of factors affecting efficacy of prenylation inhibition, like distinct features of different KRAS
mutations, tissue-specific mutational patterns, K-Ras turnover, and changes in regulation of prenylation process. Finally, we
enlist the factors that might be responsible for the large discrepancy between the outcomes in preclinical and clinical studies
including methodological pitfalls, the incomplete understanding of K-Ras protein turnover, and the variation of KRAS depen-
dency in KRAS mutant tumors.
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1 Introduction
RAS genes are one of the most frequently mutated oncogenes
in several types of cancer and their oncogenic mutations are
present up to 25% of all malignancies and mutant RAS is the
most common driver oncogene in pancreatic, colorectal, and
lung adenocarcinomas [1]. The family of Ras proteins has
three classical members, namely N-, H-, and K-Ras. The latter
exists in two isoforms, K-Ras4a and K-Ras4b, differing in the
hypervariable regions (HVR). All Ras proteins are small
GTPases that normally cycle between active GTP-bound
and inactive GDP-bound states, tightly regulated by their spe-
cific GEF and GAP proteins [2]. Oncogenic mutations occur
predominantly on codon G12, G13, and Q61. These muta-
tions impair the ability of GAP proteins to facilitate hydroly-
ses of GTP to GDP, and therefore the proteins will be consti-
tutively in active, GTP-bound state [1]. Although RAS family
members share high similarity, there are differences not only
between the hypervariable regions (HVR) of the distinct pro-
teins (166-185 aa) but also in the highly homologous catalytic
domain. The catalytic domain can be divided to lobe 1 (1-86
aa) that shares 100% homology among RAS genes, and lobe 2
(87-171) that shows site-specific amino acid variations that
probably affects intramolecular dynamics [3].
2 Distinct features and non-redundancy
of Ras proteins
A number of studies points out to differences and
unique features of the distinct RAS members. One of
the most obvious observations among these is the differ-
ences in mutation patterns. Oncogenic mutations in
KRAS are the most common, followed by NRAS and
then HRAS. Importantly, KRAS mutations are consid-
ered as a negative predictive factor for certain-targeted
therapeutic approaches [4–6].
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Of note, mutations of the RAS family show tissue and
codon specific bias. For example, KRAS is most commonly
mutated in the Ras family in pancreas (60–90%), colorectal
(30–50%), and lung (15–30%) adenocarcinomas, while
NRAS has the highest mutation rate in melanoma (15–30%)
and HRAS in head and neck cancer (6%) [1, 7]. Interestingly,
while most of the mutations in KRAS occurs in codon G12
and G13, NRAS is predominantly mutated in Q61 and HRAS
shows an intermediate behavior showing similar mutation
rates of G12 and Q61(Fig. 1) [1].
Distinct signature of the mutations can be partly explained
by differential exposures to carcinogens, as is the case in Q61
NRAS mutations in melanoma linked with UV radia-
tion, or G12C mutations in lung adenocarcinoma in as-
sociation with smoking. However, non-redundant roles
of the different proteins may also be responsible for
distinct mutational patterns [1].
Non-redundant roles of the KRAS were demonstrated in
several studies. In mice, HRAS inserted to KRAS locus can
rescue lethal development deficiencies, but results in cardio-
myopathy, suggesting non-redundant functions for KRAS [8].
Interestingly, studies with knockout mice demonstrated that
both N-Ras and H-Ras were dispensable for normal develop-
ment, while mice harboring a homozygous K-Ras null muta-
tion were not viable and die between 12 and 14 days of ges-
tation, with cardiac, liver, neurological, and hematopoietic
defects. Based on these findings, only K-Ras is indispensable
for embryonic development from the classical Ras gene fam-
ily members [9–12]. In addition, H-Ras was shown to be a
more potent activator of Pi3K [13], while K-Ras activates
better RAF/MEK/ERK pathway in vitro [14]. However, as
these experiments were carried out using overexpression
methods, results should be interpreted with caution. More re-
cently, genome-editing strategies can generate isogeneic
derivatives that harbor distinct mutations of RAS genes
expressed from the endogenous loci of the cells. These
studies also reveal differences between RAS family
members but less dramatic and more context-dependent
than the previous ones [15].
One study found that KRAS translation was lower than
HRAS in human colorectal cancer cells due to rare codon bias
in the former. If they changed KRAS codons to common ones,
they observed elevated K-Ras expression. The authors argue
that frequent KRAS mutations can be partly explained by low
K-Ras protein level, as higher levels should result in
oncogene-induced senescence [16]. Somewhat contradictory
to this finding, it has been shown that K-Ras expression is
significantly higher than the other isoforms in all tissue, al-
though the fact that the experiment was carried out in mice
limits the importance of this finding [17]. However, specific
features of the amino acid sequence of K-Ras—which are
predominantly found in the HVR region—are most expected
to regulate its distinct functions.
3 Posttranslational modifications of the HVR
region
HVR region is the most distinctive and increasingly appreci-
ated feature of Ras proteins. This domain is subjected to a
number of posttranslational modifications (PTM) that regu-
lates Ras membrane interactions. In brief, all Ras proteins
contains a CAAX motif at the C-termini, responsible for
governing prenylation—that is, attaching irreversibly a
farnesyl (C15) moiety to the 185 cystein (Fig. 1). Of note,
K-Ras protein can undergo alternative geranylgeranylation
(C20) in case farnesylation is blocked. Interestingly, this can
be observed also in N-Ras, but not in H-Ras [18].
Following prenylation, the AAX motif is cleaved by Rce1,
and the carboxyl-termini will be methylated by Icmt [19, 20].
This latter step is considered reversible; however, up to date,
no methyl esterase has unequivocally been identified that can
Fig. 1 Most common oncogenic
mutations and posttranslational
modification sites of the HVR
regions in the Ras proteins
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remove the C-termini methyl residue in Ras. Nevertheless,
polyisoprenylated methylated protein methyl esterase is a po-
tential candidate for this activity [21].
Differences in the HVR region of the KRAS isoforms (Fig.
1) have important consequences in membrane targeting and
association. While K-Ras4a—as N- and H-Ras—is subjected
to another lipid modification, named palmytoilation, K-Ras4b
can only undergo prenylation [22]. However, K-Ras4b con-
tains an isoform-specific polybasic sequence in the HVR,
which fosters association to the acidic regions of the plasma
membrane (PM) [23]. Of note, phosphorylation of S181 with-
in the polybasic sequence can further modulate K-Ras4b-PM
interaction [24].
Though K-Ras4b is considered the more important isoform
than K-Ras4a, a recent study demonstrated that K-Ras4a is
also widely expressed, and thus can also play an important
role in tumor progression. K-Ras4a—similar to N- and H-
Ras—can also be targeted to the plasma membrane by regu-
lation of palmytoilation [25]. Palmytoilation happens in the
endomembranes—in the Golgi apparatus—and fosters vesic-
ular transport of K-Ras4a to the plasma membrane.
Depalmytoilation can occur in the plasma membrane, upon
which K-Ras4a is transferred back to the Golgi.
Interestingly, K-Ras4a has also two clusters of basic residues
that are important—besides palmytoilation—for plasma
membrane association and are not found in N- and H-Ras.
Genetical modifications of either the polybasic cluster or the
palmytoilation site can reduce K-Ras4a membrane associa-
tion. However, most dramatic inhibition of colony formation
and Erk phosphorylation can be observed when the
prenylation site is ruined (C186S), suggesting that prenylation
is the more important PTM for K-Ras4a signaling [25].
4 The importance of KRAS membrane
localization
Despite the well-described process of posttranslational modi-
fication of K-Ras, it is still debated whether its membrane
association is indispensable to exert oncogenic functions es-
pecially in light of decades-long failures in targeting K-Ras
prenylation.
First, it should be noted that K-Ras proteins are considered
to regulate multiple important signaling cascades, showing a
highly complex network [26]. We will further focus on the
two most-studied signaling pathway regulated by Ras pro-
teins, namely the PI3K/AKT and RAF/MEK/ERK pathway
regulating survival and proliferation.
In case of the family of Pi3K, the membrane association is
indispensable. Class IA PI3K contains two subunits, the cata-
lytic p110 and the regulatory p85 subunit. The regulatory
subunit possesses one SH3 and two SH2 domains. Pi3K phos-
phorylates phosphoinositol molecules in the plasma
membrane (PtdIns4P, PtdIns(4,5)P2) to create PIP3. Pi3K ef-
fector proteins (including Akt, Pdk1), through their pleckstrin
homology (PH) domains, binds to PIP3, a step that is neces-
sary for them to activate signaling cascades regulating several
important cellular processes including cell growth, survival,
proliferation, and motility [27]. Of note, to fully activate Pi3K,
it seems to be necessary to bind simultaneously to K-Ras and
to activated and autophosphorylated receptor tyrosine-kinases
(RTKs) at the plasma membrane [28]. Although it is clear that
Pi3K should be at the plasma membrane while active but—to
the best of our knowledge—no direct experimental data is
available whether prenylation deficient K-Ras (e.g., C186S)
can activate Pi3K.
Concerning the RAF/MEK/ERK pathway, it is well de-
scribed that Raf activation needs dimerization [29] which
has been shown to happen in the vicinity of the plasma mem-
brane [30]. Raf proteins consist of three closely related genes,
namely ARaf, BRaf, and CRaf. Physiologically, upon up-
stream activation, specific GEFs of the Ras proteins promote
exchange of GDP to GTP, thereby activating Ras. GTP-bound
Ras recruits Raf through their Ras-binding domain (RBD),
fostering their hetero- or homodimerization. Of these, BRaf/
CRaf heterodimers are the most potent to activate downstream
signaling. Upon dimerization, phosphorylation of the Raf pro-
teins occurs; however, mechanistically, it is unclear whether it
happens by auto or transphosphorylation. Following phos-
phorylation, the Raf dimers in turn phosphorylate Mek, pass-
ing on the signal to downstream members of the signaling
cascade [31]. Of note, several studies indicated that K-Ras
localization is not homogenous at the plasma membrane, rath-
er it appears to signal through nanoclusters, small groups of
Ras proteins at distinct compartments part of the plasma mem-
brane [32]. It has also been shown experimentally that K-Ras
can form homodimers [33]. One rationale for the potential role
of Ras dimerization is based on the dimerization-dependent
nature of Raf activation and a 1:1 stochiometric ratio of Ras-
Raf interaction domains of the given proteins (i.e., the effector
domain in Ras- and Ras-binding domain of Raf). Moreover,
blocking K-Ras dimerization and nanoclustering—either by
genetic means or with specific antibodies—inhibits the effica-
cy of BRaf/CRaf heterodimerization and MAP kinase
(MAPK) activation [33, 34]. It has also been shown that
prenylation is necessary for Ras dimerization-dependent
Mapk activation. An FKB-derived dimerization domain
(DD) was genet ical ly fused to the N termini of
PAmCherry1-K-RasG12D. DDs can be “crosslinked” with a
dimerizing small molecule (that can bind two and only two
DD). Upon addition of dimerizing agent, they observedK-Ras
dimerization by photoactivated localization microscopy and
increased Mapk activation by western blot analyses.
However, when DD sequence was fused to a prenylation de-
ficient C186S KRAS, addition of dimerization agent failed to
enhance K-Ras dimerization and no activation of Mapk could
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be observed [35]. The proposed K-Ras dimerization interface
is between α-helix4 and α-helix5 of the opposing monomer.
The dimer is stabilized by a salt-bridge of D154 of one with
R161 of the other K-Ras protein, as charge reversal D154Q
mutation efficiently abrogated dimerization. However,
protein-protein interaction mediated by α-helix4 and α-
helix5 interface are suggested to be a relatively weak; thus;
it seems reasonable that plasma membrane anchoring is need-
ed to facilitate higher local concentration of K-Ras and bring
them in close proximity so that dimerization can occur [33].
Moreover, Raf cysteine-rich domains (CRD) have been
shown to promote Raf membrane association which in concert
with Ras binding, stabilizes the signaling complex at the PM,
and probably facilitate signaling by reducing the Ras-Raf-
binding fluctuations [36]. Altogether, we can conclude that
experimental data suggest that Raf activation requires Ras
membrane localization, nanoclustering, and/or dimerization.
5 HVR-associated-specific features of KRAS
All Ras proteins are tightly regulated by guanin-nucleotide
exchange factors (GEFs) and GTPase-activating proteins
(GAPs) that is necessary for their proper functions. Upon up-
stream stimuli, GEFs activates Ras proteins by promot-
ing GDP to GTP exchange, which results in conforma-
tional changes. As intrinsic GTPase activity of Ras pro-
teins are relatively slow, their inactivation needs GAPs
that foster their GTP hydrolysis rates [37]. Activating
mutations prevents this inactivating mechanism,
resulting in elevated Ras signaling.
However, K-Ras is differentially affected by several unique
regulators of its activity compared to other Ras family mem-
bers. It selectively interacts with calmodulin, protein kinase c
(PKC), and in case of K-Ras4b isoform, with phosphodiester-
ase 6 delta (Pde6δ). Of note, these interactions are all mediated
through K-Ras HVR.
It has been shown that PKC can phosphorylate K-Ras4B
on S181, reducing the strong positive charge of the HVR’s
polybasic sequence, thereby weakening interaction with the
negatively charged PM, potentially fostering membrane dis-
sociation [24]. Interestingly, Ca2+-binding calmodulin was
found to bind K-Ras through its farnesylated C-termini in a
hydrophobic pocket [38]. Of note, this interaction can hinder
PKC-mediated phosphorylation of S181, thereby preventing
an important negative regulatory mechanism. Furthermore, it
has been suggested that calmodulin along with K-Ras and
Pi3K can form a ternary complex, possibly facilitating K-
Ras-mediated activation of Pi3K—even in the abscence of
upstream RTK signaling [39]. However, this suggestion has
yet to be proved experimentally. Of note, in the absence of K-
Ras farnesylation, calmodulin could probably not bind K-Ras,
thereby altering Pi3K activation.
Furthermore, in case of K-Ras4b, but not K-Ras4A, it has
been shown that Pde6δ chaperon protein mediates PM
targeting of K-Ras4b [25]. Pde6δ—like calmodulin—also
binds K-Ras4B through the farnesylated C-termini sequester-
ing the hydrophobic protein in the cytosol. By computational
modeling and experimental data, Schmick and colleagues
demonstrated that—Pde6δ can extract K-Ras4b from the
membranes. ADP-ribosylation factor-like protein 2 (Arl2)
interacting with Pde6δ can foster release of farnesylated K-
Ras, facilitating its accumulation at the perinucleolar mem-
branes. This leads to K-Ras4b being anchored to the
recycling endosomes, which will transfer K-Ras4b to the PM.
This process is important because the endomembranes—given
their relatively higher surface—would compete for K-Ras4b
with the PM; thus, it would not be specifically enriched in the
PM [40].
6 Classes of known prenylation inhibitors
Conventionally, prenylation inhibition of K-Ras has been as-
sociated primarily with the introduction and failure of
farnesyl-transferase inhibitors (FTis). However, there are ad-
ditional two clinically approved class of drugs that are consid-
ered as potent prenylation inhibitors, namely statins and
nitrogen-containing bisphosphonates (N-bisphosphonates)
[41]. Below, we will discuss these distinct drug classes along-
side with FTis that are mechanistically differ from statins and
N-bisphosphonates. Of note, FTis are only in clinical phase II
trials for HRAS mutant head and neck cancers (clinicaltrials.
gov ID: NCT03496766; NCT02383927; NCT03719690) and
are not clinically approved for other diseases in contrast to
statins and N-bisphosphonates. These drugs interfere with
distinct steps of the prenylation process which are shown in
Fig. 2.
Mechanistically, both statins and N-bisphosphonates are
metabolic inhibitors that prevent synthesis of prenylation sub-
strates. However, they act on different levels of the
mevalonate pathway. One documented mechanism of action
that can be different between statins and N-bisphosphonates is
that the latter—by inhibiting IPP conversion to farnesyl-PP—
facilitates accumulation of IPP that in turn will be conjugated
to AMP resulting in cytotoxic ATP analogue ApppI [42].
However, other mechanisms like the dynamics of inhibition
of the mevalonate pathwaymay also lead to differential effects
of statins and bisphosphonates.
Statins inhibit the HMGCoA-reductase enzyme that con-
verts HMGCoA to mevalonate. Of note, this action is consid-
ered as the rate-limiting step in this metabolic pathway. In the
absence of mevalonate, the biosynthesis of upstream products
is shut down. Depletion of mevalonate has been demonstrated
as main mechanism of action of statins, as addition of exoge-
nous mevalonate diminishes inhibitory effects of the drugs
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[43]. Of note, though statins are being used for hypercholes-
teremia, there are some hurdles that can prevent their effec-
tiveness in vivo. First, dose-limiting toxicities may impede
reaching effective plasma concentration of these drugs [43].
Second, statins may interact with other drugs that can also
limit their use for combination therapies [44].
Nitrogen-containing bisphosphonates—but not other
bisphosphonates—have been shown to inhibit farnesyl-
pyrophosphate synthase and— to some extent—
geranylgeranyl pyrophosphate synthase. This also results in
the blocking of upstream product synthesis similar to statins
and addition of farnesyl-OH and geranylgeranyl-OH (both then
converted in the cells to farnesyl-PP and geranylgeranyl-PP,
respectively) hinders the inhibitory effects of N-
bisphosphonates [45]. Interestingly, intermediates between
mevalonate and farnesyl-PP are not involved in specific cellular
processes, and thus statins and N-bisphosphonates are expected
to have similar inhibitory profiles. Non-nitrogenous
bisphosphonates differ from N-bisphosphonates in mechanism
of action, as they exert their anticancer effects through forma-
tion of non-hydrolysable cytotoxic ATP analogues [46]. All
bisphosphonates have high affinity to mineral material of the
bones limiting their use to bone-related diseases like osteopo-
rosis or bone metastases [47]. However, lipophilic N-
bisphosphonates have been developed that can overcome this
hurdle widening therapeutic applications for non-bone-related
conditions [48]. In addition, bisphosphonates have favorable
side effect profiles as the main documented complication is
osteonecrosis of the jaw [49], which probably would occur to
a lesser extent using lipophilic bisphosphonates. However, it
has to be noted that healthy renal function with a glomerulus
filtration rate > 35 ml/min is also necessary for safe bisphos-
phonate treatment [50].
In contrast, mechanism of action of FTis is markedly differ-
ent. They specifically block activity of the farnesyl-transferase
enzyme resulting in a narrower range of inhibition than the
other two above described class of drugs inhibiting only
farnesylation. Historically, FTIs were expected to block Ras
signaling but led to an often-cited failure that hindered research
targeting Ras prenylation for years (Table 1). It was concluded
that the failure was due to alternative geranylgeranylation of K
and N-Ras [41, 51]. However, ongoing trials will showwhether
Fig. 2 Effect of prenylation
inhibition on receptor tyrosine
kinase (RTK) pathway. Distinct
classes of prenylation inhibitors
act on different levels of the
mevalonate pathway. Statins and
N-bisphosphonates shut down
farnesyl-PP synthesis, leading
to—besides inhibition of
prenylation—depletion of
dolichols and cholesterol.
Dolichols are involved in N-
glycolysation that is essential for
proper ligand binding of certain
RTKs, like EGFR. Cholesterol is
a major compound of lipid rafts,
specific microdomains of the
plasma membrane functioning as
signalization hubs in many major
signaling pathways (e.g., EGFR
and HER2). Prenylation inhibi-
tion concerns many major cellular
process, like proliferation, sur-
vival, migration (K-Ras, Rheb
Rho), vesicular transport, and au-
tophagy (Rab). Interference with
this metabolic pathway likely
leads to pleiotropic effects
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mutant H-Ras—that can only be farnesylated—can still be a
valid target of FTis in the future (clinicaltrials.gov ID:
NCT03496766; NCT02383927; NCT03719690).
7 In vitro sensitivity of KRAS mutated tumor
cells to prenylation inhibitors
There are several reviews about the in vitro effects and
mechanism of the different classes of prenylation inhib-
itors like statins, bisphosphonates, and FTis [41, 43].
Below, we are focusing on the predictive potential of
KRAS mutations and the efficacy of the aforementioned
classes of drugs.
Since the majority of the aforementioned studies only char-
acterized a limited number of cell lines, we performed an
analysis of the publicly available DEPMAP database
(https://depmap.org/repurposing/) to provide direct insight
for differences between drug classes, tissue-specific effects
using drug sensitivity data from the Repurposing Primary
Screen [52]. The screen utilizes 5-day-long treatments of
750 barcoded cell lines presenting sensitivity values of numer-
ous drugs at 2.5 μM concentration. We used data only from
the primary screen because the secondary screen does not
contain results for all three classes of prenylation inhibitors.
Data provided here show sensitivities of three classes of
prenylation inhibitors—statins, N-bisphosphonates and
farnesyl-transferase inhibitors—comparing K-Ras hotspot
mutant cell lines (G12, G13, and Q61 mutations based on
COSMIC and TCGA database) to Ras wild-type cell lines.
In order to lower drug-to-drug differences, we treated all avail-
able drugs (of PRISM repurposing primary screen) of the
distinct classes together. List of drugs included is in Table 2.
Sensitivity data of the corresponding drugs combined with
RAS mutational status and lineages using the https://
depmap.org/portal/interactive/ tool. Results were
downloaded, manually reviewed, and combined according to
drug classes (Table 2) and RASmutational status. Of note, for
tissue-specific analyses (Fig. 4), all colorectal cancer cell lines
were included; however, in case of lung cancer only, data of
lung adenocarcinoma cells were used. Respective numbers of
the cell lines included in the corresponding analyses are indi-
cated in the description of Figs. 3, 4, and 5.
Interestingly, if we compared sensitivity of all available cell
lines in the PRISM primary screen, we found marked differ-
ences between the three classes of drugs (Fig. 3). Of note,
statins and bisphosphonate, expected to behave similarly, ap-
parently showed opposite effects on K-Ras mutant versus Ras
wild-type cells. K-Ras mutants were more resistant to statins
while exhibited significantly higher sensitivity to
bisphosphonates in the same comparison. These significant dif-
ferences demonstrate that indeed these classes of drugs have
distinct impact on K-Ras mutant cells. Interestingly, no
difference could be observed in sensitivity towards FTis be-
tween K-Ras mutant and wild-type cells.
An additional important aspect is that the tissue of origin
might have an impact on the biology and drug sensitivity of
KRAS mutant cells [53]. It has been shown that prognostic
value of KRAS mutations can be dependent on the site of
metastasis, emphasizing context-dependent-specific biologi-
cal features of mutant KRAS [54–56]. In addition, mutational
patterns may also modulate tissue-specific differences. For
example, KRAS G12C, G12V, G13D, or Q61L exhibit dif-
ferential intrinsic GTPase activity, sensitivity to GAP-
mediated inactivation, or activation by GEF proteins [57,
58]. Thus, distinct properties of the different mutations along
with tissue-specific mutational patterns may mediate differen-
tial sensitivity to prenylation inhibitors.
Accordingly, when we compare the efficacy of these three
classes of these prenylation inhibitory drugs depending on tissue
of origin, pronounced sensitivity differences emerged. Figure 4
shows the comparisons of lung and colorectal adenocarcinomas.
Significant differences can only be found in lung adenocarcino-
ma; however, distinct trends can be observed depending on
tissue of origin. For example, KRASmutant colorectal cell lines
show higher resistance against N-bisphosphonates (p = 0.12)
and FTis (p = 0.17) when compared to wild-type cells.
Interestingly, we can see the opposite effects on lung adenocar-
cinomas; KRAS mutant lung adenocarcinoma cell lines are
more sensitive to N-bisphosphonates (p = 0.136) and to FTis
(p = 0.007) than wild-type cells. There are no statistically sig-
nificant differences when analyzing statins (p > 0.5).
These results clearly demonstrate the tissue-specific effects
of prenylation inhibition on K-Ras mutant cells. Moreover,
this analysis points to new questions, for instance, why FTis
can inhibit K-Ras mutant lung cancer cells despite the well-
characterized alternative geranylgeranylation of K-Ras that is
supposed to be a potential resistance mechanism against this
class of prenylation inhibitors.
Additionally, since H-Ras cannot be geranylgeranylated,
we investigated how FTis affect H-Ras mutant cell lines
(Fig. 5). Albeit there are only a limited number of HRAS
mutant cell lines, we found that FTis tended to have higher
inhibitory effects on them when compared to RAS wild-type
cell lines (p = 0.056). Of note, there are ongoing trials inves-
tigate currently FTi efficacy in HRAS mutant cancer
(clinicaltrials.gov ID: NCT03496766; NCT02383927;
NCT03719690)). These trials will clarify whether at least in
HRAS mutant tumors farnesylation inhibition is a clinically
effective approach.
Furthermore, differences in isoform expression can also
influence sensitivity to prenylation inhibitors. Of note, K-
Ras4b is known to have far the highest affinity towards
farnesyl-transferase enzymes, followed by K-Ras4a [59]. It
has been recently described that K-Ras4a is widely expressed
in different types of cancers, indicating that differential
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expression can substantially influence KRAS signaling and
regulation [25]. In addition, it has been shown that prenylation
of small GTPases is regulated by different isoforms of rap1
GTPase-GDP dissociation stimulator 1 (RAP1GDS1 or alter-
natively SMGGDS) gene. Elevated expression of Smggds has
been associated with tumor progression in breast cancer and
lung adenocarcinoma [60, 61]. Interestingly, it has been
shown that expression changes which results in an aberrant
ratio of Smggds 607:558 isoforms alters protein prenylation,
and thereby regulates their activation. This can be explained
by different functions of the isoform 607 and isoform 558:
while the former interacts with the preprenylated, newly
synthetized small GTPases, the latter interacts with the
prenylated small GTPases. [62]. We suggest that tissue-
specific expression differences of Smggds can alter sensitivi-
ties towards prenylation inhibition.
Of note, as prenylation is irreversible, prenylation inhibi-
tors can only interfere with newly synthetized K-Ras proteins.
However, despite decades-long research on K-Ras proteins,
little is known about K-Ras degradation rates and turnover.
Many mechanism has been proposed to regulate K-Ras deg-
radation, including Lztr1-cul3 [63], Nedd41 [64], and β-
Trcp1 [65]. WNT/β-CATENIN signaling has been shown to
regulate Ras stability. The authors argue that Gsk3b-mediated
phosphorylation of Ras T144 and T148 induces proteosomal
degradation of Ras proteins. However, β-catenin—through
binding to Ras—can hinder phosphorylation by GSK, thereby
inducing its stability. Stabilization of β-catenin—that can oc-
cur either by BCAT1 mutation or by loss of Apc, Axin, etc—
would thereby lead to increased stability of K-Ras [66].
Mutations in the WNT pathway frequently occur in colorectal
cancer and have been shown to cooperate with KRAS signal-
ing [67]. Resistance to prenylation inhibitors of KRASmutant
colorectal cancer (Fig. 4) may be partly due to increased sta-
bility of K-Ras proteins mediated by mutations in WNT sig-
naling pathway.
8 Resistance of mutant K-Ras proteins
against prenylation inihibition
Altogether, experimental data provides strong evidence that
posttranslational modification and specifically prenylation of
K-Ras are important to exert its functions. For decades, this
Fig. 4 Drug sensitivity values from PRISM repurposing primary screen
of lung and colorectal cancer cells. Efficacy of statins, nitrogene-
containing bisphosphonates, and farnesyl-transferase inhibitors on
KRAS mutant cells versus RAS wild-type cell lines are showed. List of
drugs included for the analyses are listed in Table 2. Interestingly, statis-
tically significant difference could only be observed in lung cancer cell
lines treated with FTis (RAS WT mean – 0.021, SEM 0.076; KRAS
MUT mean – 0.385, SEM 0.117). Note the opposite trends in sensitivity
between N-bisphosphonate- and FTi-treated colorectal and lung cancer
cells. Statistical significance was established in p < 0.05, using two-tailed
t test. n analysis was performed using the open access data of [52].
Number of cell lines included in the analyses for colorectal cancer cell
lines: RAS WT n ~ 10; KRAS MUT n ~ 20; for lung adenocarcinomas:
RASWT n ~ 28; KRASMUT n ~ 18. There is a small variation between
the number of cell lines with available data for the distinct drugs
Table 2 List of drugs of the distinctive classes of prenylation inhibitors
involved in the analyses showed in Figs. 3, 4, and 5
Statins N-bisphosphonates FTis
Atorvastatin Alendronate Lonafarnib
Lovastatin Pamidronate Tipifarnib
Mevastatin Ibandronate
Pitavastatin Neridronate
Pravastatin
Rosuvastatin
Simvastatin
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approach was considered the only option against the
undruggable-mutated K-Ras protein; however, despite all
promising experimental data, none of the clinical trials were
successful Table 1. Accordingly, we enlist the potential resis-
tance mechanisms that lead to the unsuccessful clinical
translation.
At least for FTis, lack of clinical activity on mutant
K-Ras harboring cases can be explained by alternative
geranylgeranylation that rescue membrane association of the
oncoprotein [41]. However, statins and bisphosphonates
blocking the whole mevalonate pathway shows currently no
clear escape route for K-Ras. It seems contradictory to com-
pare excess literature arguing that statins and bisphosphonates
interfere with the Ras signaling pathway with the notion that
no specific and direct activity has been reported for these
drugs on mutant K-Ras in the clinics.
Unfortunately, it has to be pointed out that common meth-
odological errors are also responsible for this discrepancy. For
example, it was recently showed that many of the commer-
cially available Ras antibodies do not recognize specifically
their intended target and/or show affinity to other proteins that
could lead to false results and conclusions [68]. Furthermore,
none of the most frequently used antibodies except for SC-31
(from Santa Cruz Biotechnology) for N-Ras performed reli-
able results in immunocitochemistry; however, many studies
show immunocitochemistry-based proof for prenylation-
induced mislocalization of Ras proteins.
Western blot experiments performed without strictly vali-
dated antibodies can also show false results even if molecular
weight of the given protein bands is similar to those of Ras
proteins. M, RRas, and many other small G proteins share
high homology with KRAS and the other genes, and will
Fig. 5 Drug sensitivity values
from PRISM repurposing primary
screen of lung and colorectal
cancer cells. Efficacy of
farnesyl-transferase inhibitors
(tipifarnib and lonafarnib) on
HRAS mutant cells versus RAS
wild-type cell lines is presented.
A strong tendency was observed,
HRAS mutant cells were more
sensitive to FTi treatment than
RAS wild-type cells (RAS WT
mean – 0.178, SEM0.026; HRAS
MUTmean – 0.554, SEM 0.243).
p value was calculated using
two-tailed t test. The open access
data of [52] was used for the
analysis. Number of cell lines in-
cluded in the analyses: RAS WT
n = 396; HRAS MUT n = 7 (cre-
ated by Graphpad Prism 5
software)
Fig. 3 Drug sensitivity values from PRISM repurposing primary screen of
all cell lines independent of tissue of origins. Efficacy of statins, nitrogen-
containing bisphosphonates, and farnesyl-transferase inhibitors on KRAS
mutant cells versus RAS wild-type cell lines are showed by analyzing the
open access data from [52]. Drugs included for the analyses are listed in
Table 2. KRAS mutant cell lines were more resistant to statins (RAS WT
mean − 0.123, SEM0.024; KRASMUTmean – 0.176, SEM0.040), while
the opposite can be observed in response to N-bisphosphonate treatment
(RAS WT mean – 0.124, SEM 0.010; KRAS MUT mean − 0.176, SEM
0.022). Statistical significance was established in p < 0.05, using two-tailed
t test. Number of cell lines included in the analyses RAS WT n ~ 390;
KRASMUT n ~ 103 (there is a small variation between the numbers of cell
lines with available data for the distinct drugs)
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appear exactly at the same height, and also undergo
prenylation. Only rigorous validation of the given antibody
can exclude the possibility that changes—either in prenylation
or activation status (e.g., via Ras-pull down assay)—is due to
other proteins very similar to K-Ras, N-Ras, or H-Ras.
Another common pitfall is to conclude successful Ras in-
hibition merely based on changes of Erk phosphorylation.
Although one of the most important signaling pathway regu-
lated by Ras proteins is indeed the Raf/Mek/Erk pathway,
changes in Erk activation status not necessarily mirrors inhi-
bition of Ras. PI3K-Erk crosstalk [69], impaired upstream
signals or regulatory feedback loop activation [70] can greatly
affect phosphorylation of Erk; thus, it is always necessary to
perform other validation experiments for mechanistic conclu-
sions. For instance, we have recently demonstrated that N-
bisphosphonate treatment resulted in elevated Erk phosphor-
ylation in K-Ras mutant harboring colorectal cancer cells, and
this effect diminished upon knockout of the mutant allele [71].
Furthermore, N-bisphosphonates can alsomodulate tumor mi-
croenvironment, for example, zoledronic acid has been shown
to activate γδT cells [72], or modulate tumor xenograft vas-
cularization [73]. These results show that we are still far away
from fully understanding how prenylation inhibition affects
Ras signaling and tumor progression. With the development
of better reagents and by avoiding these methodological pit-
falls, we will get a clearer picture on how prenylation inhibi-
tors actually affect Ras signaling.
Besides these technical issues, the promiscuous nature of
metabolic inhibitors of the mevalonate pathway further com-
plicates the K-Ras prenylation studies. Approximately 2% of
all translating proteins get prenylated; many of these are
playing indispensable roles in many cellular process [74].
These includes many small GTPases, like Rheb regulating
the PI3K/AKT/mTOR pathway; Cdc42 controlling cell cycle
[75]; Rho and Rac involved in regulation of cell skeleton and
motility [76]; Rab family proteins that controls intracellular
vesicular transport, endo and exocytosis, and autophagy [77].
For example, our group has recently demonstrated that the
efficacy of prenylation inhibition was associated with reduced
Rheb prenylation [78] or cells showed sensitivity depending
not only on NRAS but also on BRAF/PTENmutational status
[79]. In addition, in several studies, effects of statins or
bisphosphonates are mainly mediated by inhibition of
RhoA/B prenylation [41, 43].
These results suggest that mutant KRAS-dependent effects
of prenylation inhibitors can be hindered by other small
GTPases that are more sensitive or more dependent on
prenylation. Emphasizing the irreversible nature of
prenylation, we would like to point out again that prenylation
inhibitors only affect newly synthetized proteins. Therefore,
protein turnover seems to be a major factor determining sen-
sitivity towards prenylation inhibition. Unfortunately, no reli-
able data are currently available on K-Ras protein turnover
except for some sporadic reports that not allow exact determi-
nation of dynamics of degradation and synthesis rates [65,
80]. However, even these uncomplete results show that K-
Ras half-life is likely more than 12 or even 24 h, alongside
with assumptions based on the “n-rule” suggesting K-Ras
protein stability, as the second amino acid following the
cleaved initiator methionine is threonine that is considered a
“stabilizing” residue [81]. Higher stability of K-Ras compared
to other GTPases may be credited for lack of K-Ras mutation
dependence of prenylation inhibitors and probably can be the
major obstacle for evaluation of drug effects on K-Ras.
Approaches that are more specific to K-Ras prenylation—
like inhibition of C-terminal binding by Pde6δ [82] —would
counteract the obstacles derived from the (preassumed) low
turnover rate of K-Ras. Nevertheless, critical investigation of
K-Ras degradation and synthesis dynamics are urgently
needed.
In addition, not all KRAS mutant tumors exhibit similar
RAS dependence. It has been shown that proliferation and
growth of a significant proportion of KRAS mutant cancer
cell lines are not dependent on mutant KRAS. Either pharma-
cologic inhibition of KRAS G12C [83] or genetic ablation by
CRISPR-Cas9 [84] revealed a subset of cell lines that exhibits
de novo resistance to depletion of KRAS function.
Interestingly, PI3K inhibition along with KRAS targeting ex-
hibited pronounced anticancer effects [83, 84]. Of note, PI3K
pathway are a potential candidate not only in KRAS mutant
cancers, but also in solid tumors harboring NRAS mutations
[85].
Furthermore, consequences of mevalonate pathway shut-
down do not end in inhibition of prenylated proteins. The
whole squalene biosynthesis is based on this metabolic path-
way including synthesis of cholesterol, steroid hormones like
estrogens, and dolichols (involved in protein glycosylation)
[86]. This means (at the intracellular level) that signaling from
the plasma membrane will be drastically changed as choles-
terol; an important component of the lipid rafts will be deplet-
ed (Fig. 2). Lipid rafts are specific microdomains within the
membranes that are considered as important hubs for different
signalization pathways [87].
Of note, lipid raft localization of EGFR has been shown
under physiological conditions [88]. Interestingly, inhibition
of Her2 receptor localization to lipid rafts blocked breast can-
cer cell proliferation [89], and depletion of cholesterol by lov-
astatin treatment diminished resistance of breast cancer cells
to gefitinib treatment [90]. Furthermore, mevalonate pathway
shutdown blocks synthesis of dolichols that are implicated in
N-glycosylation of proteins. Of note, EGFR is known to be
heavily glycosylated and this process is necessary for ligand
binding [91]. Altered glycosylation of EGFR has been shown
in colorectal cancer samples compared to adjacent normal
tissue [92]. In addition, statin treatment altered glycosylation
of surface proteins in liver cells [93].
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Therefore, prenylation inhibition by statins and N-
bisphosphonates are expected to alter EGFR signaling by
disrupting lipid raft localization and inhibiting n-glycosyla-
tion, further complicating evaluation of efficacy on Ras, more
specifically on KRAS localization. However, FTis inhibitory
range—specifically inhibiting farnesylation—are much
narrower warranting combination studies along with
mevalonate pathway inhibitors to more specific investigation
of KRAS inhibition.
9 Concluding remarks
Despite promising feasibility of prenylation inhibition of
KRAS mutant tumors, successful clinical application of this
concept has been hindered by several factors, some of them
discussed in this review. First of all, there is a lack of prospec-
tive, randomized clinical trials specifically addressing whether
prenylation inhibitors like statins; N-bisphosphonates have
any direct antitumor effect on KRAS mutant solid tumors.
Notably, trials using FTis and statins had many handicaps like
involving advanced metastatic tumors that are very difficult to
target or utilizing low doses that are also not expected to reach
high enough concentration for antitumoral effects (Table 1).
Furthermore, recently developed lipophil ic N-
bisphosphonates are also potential applicants for targeting
even non-bone-related KRAS mutant tumors [48, 71]. N-
bisphosphonates may have better toxicity profile and lower
drug-to-drug interaction making them promising candidates
for combinational therapy [43, 44, 49].
Next, it is urgently needed to develop and utilize bio-
markers for KRAS dependency so that patients with potential
benefits for KRAS targeting can be successfully identified.
Using Ras signature may be a possible option [94], and in-
deed, one clinical trial with statin plus cetuximab/irinotecan
treatment found association of response with Ras signa-
ture (Table 1). Of note, development of this score
showed that mutation in KRAS is not a prerequisite
for KRAS dependency [94].
Last but not least, our basic understanding of KRAS biol-
ogy still has many gaps to cover. One major lack of knowl-
edge is related to the dynamics of K-Ras protein turnover.
Dynamics of K-Ras synthesis and degradation is still unclear
and these processes are crucial for prenylation inhibition as
this approach can only target newly synthesized K-Ras
proteins.
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